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RESULTS: Nearly all the medical innovations studied will result in better health
and longer life, but they will likely increase, not decrease, Medicare spending. One
exception, however, concerns innovations that improve health behavior – e.g.,
treatments that reduce the rate of obesity. Such treatments are likely to be highly
cost-effective – in many cases costing less than $10,000 per life-year saved. Simi-
larly, prevention efforts focused on the most important risk factors for disease,
especially those requiring costly treatments, could be very cost-effective.
CONCLUSIONS: Future Medicare spending through the Baby-Boomer generation
(through 2030) will increase, despite the introduction of medical innovations that
reduce disability and improve outcomes. With the possible - but important - ex-
ception of reducing obesity, Medicare costs will dramatically increase consequent
to the overriding impact of the demographic shifts in the elderly population. Health
policy makers need to incorporate these findings in their health policy initiatives.
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OBJECTIVES: Compare clinical and economic outcomes between post-menopausal
women treated with combined estrogen and progestogen hormone therapy (HT)
within 1 and 1-2 years after diagnosis. METHODS: A retrospective analysis of
women age 45 or older from a large U.S. health plan (April 2002-September 2010)
was conducted. The first HT prescription during the identification period (April
2005-September 2008) was identified as the index date. Patients were selected if
they initiated HT treatment within 2 years of menopause diagnosis, and had 3
years of continuous health plan enrollment before (pre-period) and 2 years after
the index date (post-period). Patients with evidence of post-period pregnancy or
pre-period other HT treatment were excluded. Two cohorts were created based on
HT initiation date (Cohort A: HT initiated within 1 year of diagnosis; Cohort B: 1-2
years after diagnosis). Propensity score matching (PSM) was used to adjust for
baseline differences in age, region, procedure used, comorbidities, and healthcare
utilizations during the pre-period. RESULTS: Among 4268 eligible patients, 69.3%
(N2956) were included in Cohort A and 30.7% (N1871) in Cohort B. After PSM,
1310 patients from each group werematched. Patients prescribed HTwithin 1 year
of menopause diagnosis (Group A) were less likely to have Dual-Energy X-RAY
Absorptiometry (DEXA) scans and osteopenia than patients treated between 1-2
years after menopause diagnosis. In addition, patients with earlier treatment
showed a highermedication possession ratio (MPR) (0.49 vs. 0.46, p0.272). Health-
care costs and utilizations remained similar, except patients with early HT treat-
ment had significantly lower emergency room visit rates (22.9% vs. 26.5%, p0.033)
than patients with late HT treatment. CONCLUSIONS: Patients initiating HTwithin
1 year of menopause diagnosis had fewer comorbidities, directionally higher MPR
but not significant, and lower emergency roomvisit rates thanwomen initiatingHT
between 1-2 years. Other clinical and economic outcomes were similar.
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OBJECTIVES: To identify the potential size of the population in Canada eligible for
infertility screening as a prerequisite to publicly provided funding, and to estimate
the associated costs. METHODS: Using the Canadian Fertility Cost Model frame-
work, an age-specific decision model was developed to estimate the potential size
of theCanadian population eligible for infertility screening. Based on thenumber of
women presenting for annual comprehensive general assessments to their family
physicians, and published age-specific data on the number of women without
children, we estimated the number of Canadian couples eligible for infertility
screening. The total cost of screening was calculated using sex-specific infertility
screening costs. The potential number of live births was also estimated. Sensitivity
analyses were performed. All costs were expressed in 2009 Canadian dollars.
RESULTS: Based on the number of women who undergo an annual physician gen-
eral assessment in Canada, the number of women eligible for infertility screening
was estimated. According to published studies around 50% of infertile women
might seek medical assistance; resulting in approximately 75,000 women aged
30-45 being screened. Assuming 50% of their partners would come for screening,
37,500 males would be screened for infertility. The annual cost of screening has
been estimated at $10.6 million. The resulting number of live births would be
15,800. The proportion of total screening cost attributed to women aged 30-34,
35-39, and 40-45 is 36%, 28% and 36%, respectively. The proportion of total live
births in each age group is 51%, 31% and 18%, respectively. CONCLUSIONS: We
estimated the potential costs of infertility screening, a prerequisite to publicly
provided infertility treatments. Recent studies of selected European countries have
established that public subsidy of IVFmight represent sound fiscal policy, and that
lifetime future tax revenues over an average lifetime of an IVF offspring might
return a positive net value.
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OBJECTIVES: The objective of this study was to investigate the societal costs in
employed patients not able towork due to chronic, long-term, or terminal illness in
Germany and France for potential inclusion in health economic models and hence
influence on decision making.METHODS: Societal costs were investigated by col-
lecting and analysing labour costs, disability benefit and home care benefits in
Germany and France for employed patients. Costs were derived from publicly
available literature or databases. The costs were analysed over 1, 3 and 5 year time
horizons. RESULTS: The analysis showed that public costs could play an important
role in health economic analyses in Germany and France. Productivity loss, disabil-
ity pension and home care benefit during the first year of sickness were on average
€41,224 per employed patient in Germany. It was assumed that patients did not
work during the year at all. The societal costs were €44,952 in France per employed
patient for the first year of sickness. The year 3 per employed patient cumulative
costs in Germany and France were €144,280 and €158,464, respectively. The year 5
per employed patient cumulative costs in Germany and France were €254,205 and
€271,975, respectively. CONCLUSIONS: Societal costs associated with long term
sickness are not insignificant in Germany and France. Although indirect costs are
currently not included as part of reimbursement criteria in Germany and France,
this analysis suggests that the inclusion of these should be considered for standard
health economic analyses where possible. The results are of interest when com-
paring two treatment regimenswhere patients have differing ability to work either
during or after the treatment, or where a majority of patients are employed. The
overall perspective could support decision making beyond assessment of clinical
benefits alone.
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OBJECTIVES: Conventional pricing theory suggests that therapies with additional
benefits over an existing option may garner a higher price to account for this
incremental value/benefit. For reformulated therapies such as extended-release
(ER) products, common patient benefits (e.g. potentially reduced pill burden and
side effects) should provide enough incremental benefit to warrant a price higher
than the immediate-release (IR) formulation of the samemolecule. The objective of
this study is to quantify the intrinsic value of ER formulations by exploring the price
comparison between ER and IR formulations. METHODS: To identify therapies of
interest, a search of the Epocrates drug database was conducted and all therapies
with names indicative of reformulated products were analyzed. The price of each
ERproductwas captured for the first day ofmarket availability and compared to the
branded IR formulation. An analysis of IR generic entry and the time elapsed from
branded IR launch was conducted to determine if these confounding factors ex-
plained the observations. RESULTS: Of the 19 ER products that were analyzed, the
majority (58%) had prices lower than the IR product. Only one-quarter (26%), had
prices higher than the IR product and the remaining products had equivalent
prices. Generic entry did not correlate with the observed price comparisons be-
tween ER and IR formulations. CONCLUSIONS: The percentage price difference
between branded ER and branded IR products did not uncover a standard incre-
mental value that would indicate there is an intrinsic value provided by ER formu-
lations. An analysis of generic entry failed to show that a reduced price reference
may be a factor for products with lower ER prices. It is likely that pricing decisions
for the ER products included unique price sensitivity studies and considered con-
fidential corporate strategy, as is best practice.
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OBJECTIVES: The purpose of this study was to compare brand and generic medi-
cation adherence in key therapeutic classes, particularly among the generic, and
the non-preferred and preferred brand initiators.METHODS: CVS Caremark phar-
macy claims data (July 1, 2008–July 1, 2011) were analyzed for patients who initi-
ated therapy at retail.We comparedmedication persistence and compliance over a
12-month period in 4 therapeutic classes: angiotensin-converting enzyme inhibi-
tors (ACEIs), angiotensin-II receptor blockers (ARBs), HMG-CoA reductase inhibi-
tors (statins), Biguanides. To qualify for the study, the patients had to be continu-
ously eligible for benefits a total of 18 months, with the additional 6 months to
identify initiators. We compared Medication Possession Ratio (MPR), Medication
Persistence, Proportion of Days Covered (PDC), and the First Fill Persistency (FFPR)
among generic, non-preferred and preferred brand utilizers, on the therapeutic
class level based on GPI-4 codes (ACEIs:3610- ARBs:3615- STATINs:3940- Bigua-
nides:2725). Bi-variate and multi-variate analyses, including linear and logistic re-
gressionwere conducted using SASVersion 9.1with SAS/STAT. RESULTS:A total of
1.1 million patients met inclusion criteria. Compared to brand utilizers, generic
utilizers’ persistency over 12-month was 3% (p0.001) higher; their adjusted 12-
months MPR was 2.65% (p0.001) higher. Generic utilizers were also 17% (p0.001)
more likely to achieve optimal adherence (MPR  80%), and were 18% (p0.001)
more likely to remain on therapy after the first fill. The utilizers of non-preferred
brands had a 1%-5% lower persistence over a 12-month period than did patients on
preferred brandmedications. Finally, thosewho started on a brand and switched to
a generic had 2-5% higher PDC, and 0.6%-2.5% (p0.001) higher 12-months persis-
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